Astrocytoma, IDH-mutant, grade 3
MONDO:0956995An IDH-mutant anaplastic astrocytoma that is characterized by the presence of increased mitotic activity and anaplastic features.
2844 clinical trials for this condition and its sub-types, 16 tagged with Astrocytoma, IDH-mutant, grade 3 itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →-
Oral Brain-Penetrating drug tested against aggressive IDH1-Mutant gliomas
Disease control Not yet recruitingResearchers are testing an oral drug called safusidenib in adults newly diagnosed with IDH1-mutant grade 3 oligodendroglioma or astrocytoma, two types of brain tumor. Safusidenib is designed to cross into the brain and block the mutated IDH1 enzyme that drives these tumors. All 2…
Phase 2 • Sponsor: University of Zurich • Aim: Disease control
Last updated Sep 21, 2026 17:00 UTC
-
New hope for brain tumor patients when standard drug fails
Disease control Not yet recruitingThis study tests an experimental drug called safusidenib in people with a slow-growing brain tumor (IDH1-mutant glioma) whose tumor got worse while on the standard drug vorasidenib. Up to 40 participants take safusidenib pills twice daily to see if the tumor shrinks or stops grow…
Phase 2 • Sponsor: Nuvation Bio Inc. • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC